12:00 AM
 | 
May 07, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Fampyra fampridine regulatory update

The German Institute for Quality and Efficiency in Health Care (IQWiG) said Fampyra fampridine from Biogen Idec provides no additional benefit over physiotherapy in multiple sclerosis patients with walking disability. According to IQWiG, Biogen Idec only submitted data indirectly comparing Fampyra against physiotherapy....

Read the full 193 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >